PGR and breast cancer: In the treatment of breast cancer patients classical clinicopathological parameters together with estrogen (ER) and progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2) status are currently applied to stratify patients into high and low risk groups [2].